Data / Drug companies / NCS HealthCare of Ky, LLC DBA Vangard Labs
NCS HealthCare of Ky, LLC DBA Vangard Labs: 315 products in the FDA NDC directory, labeler code 0615
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
NCS HealthCare of Ky, LLC DBA Vangard Labs (labeler code 0615) lists 315 products in the FDA National Drug Code Directory, covering 134 finished drugs by generic name. By type: 301 prescription drugs, 14 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 14, 2026.
The request: Watch NCS HealthCare of Ky, LLC DBA Vangard Labs (FDA labeler code 0615): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0615
- Products in commercial distribution
- 315
- Packages
- 554
- Finished drugs by generic name
- 134
- Prescription products
- 301
- Over the counter products
- 14
- Started marketing in the last 12 months
- 6
- Products with a marketing end date set
- 13
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 294 | 93.3% |
| New drug applications (NDA) | 10 | 3.2% |
| Over the counter monograph drugs | 9 | 2.9% |
| Other unapproved drugs | 2 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 301 | 95.6% |
| Over the counter drugs | 14 | 4.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 148 | 47% |
| Tablet, film coated | 91 | 28.9% |
| Capsule | 21 | 6.7% |
| Tablet, extended release | 20 | 6.3% |
| Capsule, extended release | 7 | 2.2% |
| Tablet, delayed release | 7 | 2.2% |
| Tablet, film coated, extended release | 6 | 1.9% |
| Capsule, delayed release | 6 | 1.9% |
| Tablet, chewable | 4 | 1.3% |
| Capsule, liquid filled | 3 | 1% |
| Tablet, coated | 2 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mirtazapine | 0615-8663 | Tablet, film coated | Generic drugs (ANDA) | May 14, 2026 |
| Amlodipine Besylate | 0615-8654 | Tablet | Generic drugs (ANDA) | December 6, 2025 |
| Amlodipine Besylate | 0615-8652 | Tablet | Generic drugs (ANDA) | December 6, 2025 |
| Amlodipine Besylate | 0615-8647 | Tablet | Generic drugs (ANDA) | December 6, 2025 |
| Acamprosate Calcium | 0615-8660 | Tablet, delayed release | Generic drugs (ANDA) | December 1, 2025 |
| Loratadine antihistamine | 0615-8217 | Tablet | Generic drugs (ANDA) | November 20, 2025 |
| Oxcarbazepine | 0615-8636 | Tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| Oxcarbazepine | 0615-8635 | Tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| Oxcarbazepine | 0615-8634 | Tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| Fluoxetine | 0615-8612 | Capsule | Generic drugs (ANDA) | July 11, 2025 |
| Adult Low Dose Aspirin | 0615-8613 | Tablet, delayed release | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen | 0615-8610 | Tablet, film coated | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen | 0615-8609 | Tablet, film coated | Over the counter monograph drugs | July 9, 2025 |
| Acetaminophen | 0615-8608 | Tablet, film coated | Over the counter monograph drugs | July 9, 2025 |
| Ciprofloxacin | 0615-8630 | Tablet, film coated | Generic drugs (ANDA) | March 27, 2025 |
| Cyclobenzaprine Hydrochloride | 0615-8665 | Tablet | Generic drugs (ANDA) | February 19, 2025 |
| Bumetanide | 0615-8616 | Tablet | Generic drugs (ANDA) | January 16, 2025 |
| Bumetanide | 0615-8615 | Tablet | Generic drugs (ANDA) | January 16, 2025 |
| Bumetanide | 0615-8614 | Tablet | Generic drugs (ANDA) | January 16, 2025 |
| Benzonatate | 0615-8661 | Capsule | Generic drugs (ANDA) | July 26, 2024 |
| Divalproex sodium | 0615-8588 | Tablet, delayed release | Generic drugs (ANDA) | June 26, 2024 |
| Divalproex sodium | 0615-8587 | Tablet, delayed release | Generic drugs (ANDA) | June 26, 2024 |
| Divalproex sodium | 0615-8586 | Tablet, delayed release | Generic drugs (ANDA) | June 26, 2024 |
| Pravastatin sodium | 0615-8542 | Tablet | Generic drugs (ANDA) | June 1, 2024 |
| Pravastatin sodium | 0615-8541 | Tablet | Generic drugs (ANDA) | June 1, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.